US · Healthcare · Medical Devices
EPS came in at 0.78 against a street estimate of 0.73 — a beat of 6.8%.
Analysts rate Edwards Lifesciences Corp a buy (23 buy, 6 hold, 0 sell out of 29) with an average price target of $101.81.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.20% |
| Vanguard Capital Management, LLC | 6.53% |
| Vanguard Portfolio Management, LLC | 4.58% |
| State Street Corp | 4.57% |
| JPMorgan Chase & Co | 3.95% |
| Wellington Management Company LLP | 2.92% |
| Geode Capital Management, LLC | 2.68% |
| Bank of New York Mellon Corp | 2.44% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 EDWARDS LIFESCIENCES CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • No financial results or numerical performance data disclosed in this filing • | 2026-08-28 |
| Quarterly report · Q2 2026 EDWARDS LIFESCIENCES CORPORATION – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 Net Sales: $1,741.0 million (vs. $1,532.2 million in Q2 2025) – u | 2026-08-04 |
| Results announced · Q3 2026 EDWARDS LIFESCIENCES CORPORATION – Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 total sales: $1.74 billion, up 13.6% year-over-year (12.5% con | 2026-07-23 |
| Board / officer change · Q2 2026 EDWARDS LIFESCIENCES CORPORATION – FORM 8-K SUMMARY Report Date: May 7, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Edwards Lifesciences Corporation i | 2026-05-08 |
| Quarterly report · Q1 2026 EDWARDS LIFESCIENCES CORPORATION – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net sales Q1 2026: $1,648.6 million vs. $1,412.7 million Q1 2025 (+16.7% | 2026-05-06 |
| Board / officer change · Q2 2026 EDWARDS LIFESCIENCES CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • New Chief Financial Officer appointment effective May 29, 2026 • Sign-on bonu | 2026-05-04 |
| Proxy statement · Q2 2026 EDWARDS LIFESCIENCES CORPORATION – 2026 PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of nine director nominees for one-year | 2026-03-26 |
| Annual report FY2025 EDWARDS LIFESCIENCES CORPORATION — 2025 FORM 10-K SUMMARY HEADLINE NUMBERS • Market cap (as of June 30, 2025): $45.9 billion • Shares outstanding (a | 2026-02-25 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Edwards Lifesciences Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.